{
    "nct_id": "NCT04887194",
    "official_title": "A Two-cohort, Two-part, Phase 1, Multicenter, Open-label, Fixed-sequence, Drug-Drug Interaction and QTc Assessments of Sitravatinib Followed by Combination Treatment With Nivolumab in Patients With Advanced Solid Malignancies",
    "inclusion_criteria": "* Confirmed diagnosis of unresectable advanced/metastatic solid tumor\n* Life expectancy of at least 3 months\n* Adequate bone marrow and organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Ongoing medical condition or need for treatment with medication that may affect the PK of study treatments during Part 1\n* Immunocompromising conditions\n* Impaired heart function\n* Active or prior documented autoimmune disease",
    "miscellaneous_criteria": ""
}